← Leaderboards
Christopher D Pack
Emory University
$4,540,154
Attributed
$6,790,248
Total exposure
5
Grants
3
Lead (contact PI)
Attributed= this PI's even-split share of every grant they're on (the fair, additive number). Exposure = full size of all those grants.
Funding over time
peak $1.6M · FY2008–22$2M$1.5M$1M$500K$0
'08
'09
'10
'11
'12
'13
'14
'15
'16
'17
'18
'19
'20
'21
'22
Funding mix
By agency
NIH$6,790,248 · 5
By mechanism
R44$3,954,038 · 2
R01$2,640,173 · 1
R43$144,759 · 1
F32$51,278 · 1
Top collaborators
- Periasamy Selvaraj9 shared
- Kamal V. Kannan3 shared
Most similar at Emory University
Same institution · by research overlap
- Periasamy Selvaraj$6,170,340
- Francois J Villinger$61,853,654
- John D Roback$16,074,929
- Sean R Stowell$18,165,764
- Aftab A. Ansari$22,344,206
Others in their field
Top investigators on “Tumor”
- David Heimbrook · Leidos Biomedical Research, Inc.$636,492,067
- Leonard Freedman · Leidos Biomedical Research, Inc.$360,535,780
- Gregory H Reaman · National Childhood Cancer Foundation$208,276,509
- Richard K. Wilson · Washington University$203,917,615
- Norman Wolmark · Nsabp Foundation, Inc.$177,323,696
- Ronald T Mitsuyasu · University Of California Los Angeles$138,361,819
Research focus
TumorEffective TherapyGlycolipidsTumor TissueMalignant NeoplasmsMembraneProteinsProgesterone ReceptorsTriple-Negative Invasive Breast CarcinomaMouse ModelVaccinesVesicleAntigensMalignant Breast NeoplasmEstrogen ReceptorsErbb2 GeneCost EffectiveImmunityNeoplasm MetastasisAutologousAntigen TargetingBreast Cancer PatientCancer VaccinesInterleukin-12
Grant awards (18)
Clinical Evaluation of a Personalized Vaccine Immunotherapy in Combination with Checkpoint Inhibitors for Triple Negative Breast Cancer$938,597
R44 · FY2022 · CA · contact PI
Clinical Evaluation of a Personalized Vaccine Immunotherapy in Combination with Checkpoint Inhibitors for Triple Negative Breast Cancer$59,382
R44 · FY2022 · CA · contact PI
Clinical Evaluation of a Personalized Vaccine Immunotherapy in Combination with Checkpoint Inhibitors for Triple Negative Breast Cancer$34,640
R44 · FY2022 · CA · contact PI
Clinical Evaluation of a Personalized Vaccine Immunotherapy in Combination with Checkpoint Inhibitors for Triple Negative Breast Cancer$1,061,403
R44 · FY2021 · CA · contact PI
Membrane-based immunotherapy for triple negative breast cancer- a partnered approach$480,895
R01 · FY2020 · CA
Membrane-based immunotherapy for triple negative breast cancer- a partnered approach$54,324
R01 · FY2020 · CA
Membrane-based immunotherapy for triple negative breast cancer- a partnered approach$468,979
R01 · FY2019 · CA
IND enabling studies for a personalized immunotherapy for triple negative breast cancer$80,133
R44 · FY2019 · CA
Membrane-based immunotherapy for triple negative breast cancer- a partnered approach$54,778
R01 · FY2019 · CA
Membrane-based vaccine with checkpoint blockade for triple negative breast cancer$1,079,344
R44 · FY2018 · CA
Membrane-based immunotherapy for triple negative breast cancer- a partnered approach$483,484
R01 · FY2018 · CA
Membrane-based immunotherapy for triple negative breast cancer- a partnered approach$56,472
R01 · FY2018 · CA
Membrane-based vaccine with checkpoint blockade for triple negative breast cancer$700,539
R44 · FY2017 · CA
Membrane-based immunotherapy for triple negative breast cancer- a partnered approach$482,114
R01 · FY2017 · CA
Membrane-based immunotherapy for triple negative breast cancer- a partnered approach$56,472
R01 · FY2017 · CA
Membrane-based immunotherapy for triple negative breast cancer- a partnered approach$502,655
R01 · FY2016 · CA
A membrane-based immunotherapy for triple negative breast cancer$144,759
R43 · FY2013 · CA · contact PI
Regulation of CD8 T cell responses to polyoma virus infection$51,278
F32 · FY2008 · AI · contact PI